{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:44:53Z","timestamp":1790232293286,"version":"4.1.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T00:00:00Z","timestamp":1615852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"COREVIH Centre-Poitou Charentes"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Low HIV reservoirs may be associated with viral suppression under a lower number of antiretroviral drugs. We investigated tenofovir disoproxil fumarate\/emtricitabine as a maintenance strategy in people living with HIV (PLHIV) with low HIV-DNA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>TRULIGHT (NCT02302547) was a multicentre, open-label, randomized trial comparing a simplification to tenofovir disoproxil fumarate\/emtricitabine versus a triple regimen continuation (tenofovir disoproxil fumarate\/emtricitabine with a third agent, control arm) in virologically suppressed adults with HIV-DNA &amp;lt;2.7\u2009log10 copies\/106 PBMCs and no prior virological failure (VF). The primary endpoint (non-inferiority margin 12%) was the percentage of participants with a plasma viral load (pVL) &amp;lt;50\u2009copies\/mL in ITT (Snapshot approach) and PP analyses at Week 48 (W48).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 326 participants screened, 223 (68%) were randomized to the tenofovir disoproxil fumarate\/emtricitabine arm (n\u2009=\u2009113) or control arm (n\u2009=\u2009110). At W48, the tenofovir disoproxil fumarate\/emtricitabine and control arms maintained a pVL\u2009&amp;lt;\u200950\u2009copies\/mL in 100\/113 (88.5%) and 100\/110 (90.9%) participants, respectively (ITT difference 2.4%, 95% CI \u20135.9 to 10.7; PP difference 3.4%, 95% CI \u20134.2 to 11.0). Six VFs occurred in the tenofovir disoproxil fumarate\/emtricitabine arm (two with emerging mutations M184V and K65R) versus two in the control arm (ITT difference 3.5%, 95% CI \u20131.9 to 9.4). All VFs were resuppressed after treatment modification.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Although non-inferiority was shown, simplification to tenofovir disoproxil fumarate\/emtricitabine should not be used for most PLHIV because of a low risk of VF with resistance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkab038","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T05:32:57Z","timestamp":1612416777000},"page":"1564-1572","source":"Crossref","is-referenced-by-count":2,"title":["Tenofovir disoproxil fumarate and emtricitabine maintenance strategy in virologically controlled adults with low HIV-1 DNA: 48 week results from a randomized, open-label, non-inferiority trial"],"prefix":"10.1093","volume":"76","author":[{"given":"Thierry","family":"Prazuck","sequence":"first","affiliation":[{"name":"Service des Maladies Infectieuses et Tropicales, CHR d\u2019Orl\u00e9ans\u2014La Source, Orl\u00e9ans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Verdon","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses, CHU C\u00f4te de Nacre, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwena\u00ebl","family":"Le Moal","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses, CHU La Mil\u00e9trie, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fa\u00efza","family":"Ajana","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses, CHU Lille Tourcoing, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Bernard","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses, CHU Bretonneau, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Sunder","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses et Tropicales, CHG de Niort, Niort, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Roncato-Saberan","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses, Groupe Hospitalier de La Rochelle\u2014R\u00e9 \u2013 Aunis, La Rochelle, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Ponscarme","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses, CHU Saint-Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7301-2614","authenticated-orcid":false,"given":"Manuel","family":"Etienne","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses, CHU de Rouen, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Viard","sequence":"additional","affiliation":[{"name":"Centre de Diagnostic et Th\u00e9rapeutique, H\u00f4tel-Dieu, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Pasdeloup","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, CH de Saintonge, Saintes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuliana","family":"Darasteanu","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses, CH de Chartres, Chartres, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Pialoux","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses, CHU Tenon, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"de la Blanchardi\u00e8re","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses, CHU C\u00f4te de Nacre, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Avettand-F\u00e8no\u00ebl","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Facult\u00e9 de M\u00e9decine, INSERM, U1016, CNRS, UMR8104, Laboratoire de Microbiologie clinique, unit\u00e9 de virologie, CHU Necker, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4774-5590","authenticated-orcid":false,"given":"Jean-Jacques","family":"Parienti","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses, CHU C\u00f4te de Nacre, Caen, France"},{"name":"EA 2656 GRAM 2.0, Caen Universit\u00e9, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2264-4822","authenticated-orcid":false,"given":"Laurent","family":"Hocqueloux","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses et Tropicales, CHR d\u2019Orl\u00e9ans\u2014La Source, Orl\u00e9ans, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the TRULIGHT Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Fourmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elody","family":"Mureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Juteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Giraudeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Dargere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Michon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Baldoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,16]]},"reference":[{"key":"2021051408581609700_dkab038-B1","year":"2019"},{"key":"2021051408581609700_dkab038-B2","year":"2019"},{"key":"2021051408581609700_dkab038-B3","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2013.10.001","article-title":"Systemic effects of inflammation on health during chronic HIV infection","volume":"39","author":"Deeks","year":"2013","journal-title":"Immunity"},{"key":"2021051408581609700_dkab038-B4","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1473-3099(15)00056-0","article-title":"Future challenges for clinical care of an ageing population infected with HIV: a modelling study","volume":"15","author":"Smit","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2021051408581609700_dkab038-B5","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJM199810293391801","article-title":"Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team","volume":"339","author":"Havlir","year":"1998","journal-title":"N Engl J Med"},{"key":"2021051408581609700_dkab038-B6","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1056\/NEJM199810293391802","article-title":"A randomised trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Tril\u00e8ge (Agence Nationale de Recherches sur le SIDA 072) Study Team","volume":"339","author":"Pialoux","year":"1998","journal-title":"N Engl J Med"},{"key":"2021051408581609700_dkab038-B7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(15)00096-1","article-title":"Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial","volume":"15","author":"Arribas","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2021051408581609700_dkab038-B8","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(15)00097-3","article-title":"Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial","volume":"15","author":"Perez-Molina","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2021051408581609700_dkab038-B9","first-page":"1163","article-title":"Treatment simplification to atazanavir\/ritonavir\u2009+\u2009lamivudine versus maintenance of atazanavir\/ritonavir\u2009+\u2009two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomised trial (ATLAS-M","volume":"72","author":"Di Giambenedetto","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021051408581609700_dkab038-B10","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/cix734","article-title":"Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of human immunodeficiency virus type 1 viral suppression: randomised, open-label, noninferiority DUAL-GESIDA 8014-RIS-EST45 trial","volume":"65","author":"Pulido","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021051408581609700_dkab038-B11","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"2021051408581609700_dkab038-B12","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"2021051408581609700_dkab038-B13","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"2021051408581609700_dkab038-B14","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose two-drug regimen versus continuing a tenofovir alafenamide-based three- or four-drug regimen for maintenance of virologic suppression in adults with HIV-1: phase 3, randomised, non-inferiority TANGO study","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021051408581609700_dkab038-B15","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1473-3099(14)70736-4","article-title":"Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial","volume":"14","author":"Cahn","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2021051408581609700_dkab038-B16","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/S0140-6736(14)61170-3","article-title":"Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001\/ANRS143 randomised non-inferiority trial","volume":"384","author":"Raffi","year":"2014","journal-title":"Lancet"},{"key":"2021051408581609700_dkab038-B17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"2021051408581609700_dkab038-B18","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/jac\/dky497","article-title":"Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort","volume":"74","author":"Cuzin","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2021051408581609700_dkab038-B19","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomised comparative clinical trials","author":"Sax","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021051408581609700_dkab038-B20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1310\/hct1403-120","article-title":"Long-term HIV-1 virologic control in patients on a dual NRTI regimen","volume":"14","author":"Prazuck","year":"2013","journal-title":"HIV Clin Trials"},{"key":"2021051408581609700_dkab038-B21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/jmv.21390","article-title":"LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01)","volume":"81","author":"Avettand-F\u00e8no\u00ebl","year":"2009","journal-title":"J Med Virol"},{"key":"2021051408581609700_dkab038-B22","doi-asserted-by":"crossref","first-page":"ofz051","DOI":"10.1093\/ofid\/ofz051","article-title":"Risk and cost associated with drug-drug interactions among aging HIV patients receiving combined antiretroviral therapy in France","volume":"6","author":"Demessine","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2021051408581609700_dkab038-B23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2288-6-46","article-title":"Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance","volume":"6","author":"Parienti","year":"2006","journal-title":"BMC Med Res Methodol"},{"key":"2021051408581609700_dkab038-B24","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/infdis\/jir518","article-title":"Factors associated with virological failure in HIV-1-infected patients receiving darunavir\/ritonavir monotherapy","volume":"204","author":"Lambert-Niclot","year":"2011","journal-title":"J Infect Dis"},{"key":"2021051408581609700_dkab038-B25","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1097\/QAD.0b013e32835646e0","article-title":"Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study","volume":"26","author":"Guiguet","year":"2012","journal-title":"AIDS"},{"key":"2021051408581609700_dkab038-B26","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nri3262","article-title":"Towards an HIV cure: a global scientific strategy","volume":"12","author":"Deeks","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"2021051408581609700_dkab038-B27","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/jac\/dks533","article-title":"Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts","volume":"68","author":"Hocqueloux","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2021051408581609700_dkab038-B28","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1128\/CMR.00015-16","article-title":"Total HIV-1 DNA, a marker of viral reservoir dynamics with clinical implications","volume":"29","author":"Avettand-F\u00e8no\u00ebl","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"2021051408581609700_dkab038-B29","doi-asserted-by":"crossref","first-page":"102779","DOI":"10.1016\/j.ebiom.2020.102779","article-title":"Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomised, pilot clinical trial (ART-PRO)","volume":"55","author":"De Miguel","year":"2020","journal-title":"EBioMedicine"},{"key":"2021051408581609700_dkab038-B30","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1093\/jac\/dkaa287","article-title":"Impact of archived M184V\/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV","volume":"75","author":"Chen","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2021051408581609700_dkab038-B31","doi-asserted-by":"crossref","first-page":"ofy113","DOI":"10.1093\/ofid\/ofy113","article-title":"Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study","volume":"5","author":"Gagliardini","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2021051408581609700_dkab038-B32","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/jac\/dkp462","article-title":"Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients","volume":"65","author":"Valantin","year":"2010","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/6\/1564\/37927546\/dkab038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/6\/1564\/37927546\/dkab038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T09:02:24Z","timestamp":1620982944000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/6\/1564\/6173723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,16]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,3,16]]},"published-print":{"date-parts":[[2021,5,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab038","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2021,3,16]]}}}